Guardant Health’s Guardant360 Response™ Receives The 2021 Product Innovation Award By Lucintel

By Author: Lucintel LLC
Total Articles: 4803
Comment this article

Based on recent research on the Liquid Biopsy market, Lucintel is pleased to announce Guardant Health’s Guardant360 Response™ as the recipient of the “2021 Product Innovation Award in the Liquid Biopsy Market”. Lucintel chose Guardant Health for this award because of its novel blood test method, which predicts and monitor patient’s treatment response quickly as compared to the traditional radiographic assessment, such as X-rays, computerized tomography (CT) scans, and magnetic resonance imaging (MRI) tests. Therefore, it enables the oncologists to make first- and second-line of treatment decisions, and helps in extending the probability of survival in cancer patients.

Guardant Health’s Guardant360 Response™ is the first blood-only liquid biopsy which enables oncologists to view molecular response, or changes in circulating tumor DNA (ctDNA) levels, from a simple blood drawn to analyse in advance whether a patient is responding to immunotherapy or targeted treatment. It has the capability to detect changes in ctDNA and predict treatment response 8 weeks earlier than current standard-of-care radiological and ...
... imaging scans.

Guardant Health’s Guardant360 Response™ provides the oncologists with an important tool that helps in determining whether to continue, stop, or explore other treatment options for their patients with late-stage or metastatic cancer. Thus, it provides oncologists with a more complete view of their patient’s tumor evolution and resistance to interventional therapies, including immunotherapies.

Lucintel’s awards in innovation and industry excellence recognize outstanding achievements and latest endeavors by companies in various industries, identifying the most successful, innovative, and forward-thinking companies and products in business today. Lucintel awards are based on systematic and detailed research on the relevant markets to identify and recognize the most successful recent innovations. These initiatives enable companies to demonstrate high levels of industry impact and benefits to end users. Lucintel awarded number of companies in various award categories. Please find below list of award winners: www.lucintel.com/award-of-excellence.aspx. To know more contact Lucintel at +1-972-636-5056 or click on this link helpdesk@lucintel.com

About Lucintel
Lucintel, a premier market research and management consulting firm based in Dallas, Texas, has served over 1,000 clients for over 20 years. With our in-depth analysis and sage advice, Lucintel offers solutions for your growth through game changing ideas and analysis of robust markets and unmet needs. Lucintel has been quoted in esteemed publications, including The Wall Street Journal, ZACKS, and The Financial Times. For further information, visit www.lucintel.com.

About Guardant Health

Guardant Health is based in United States and is a leading precision oncology company, which focuses on helping conquer cancer globally with the usage of its proprietary blood tests, vast data sets and advanced analytics. It leverages its capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer. Guardant Health’s Guardant360 Response™ empowers oncologists to optimize treatment, and know confidently what to do next in the treatment process, as shown in www.guardanthealth.com/solutions/. Company aims to address the needs of asymptomatic individuals eligible for cancer screening. For further information, www.guardanthealth.com/

Contact:
Sabonn Dammarell
Lucintel
Dallas, Texas, USA
Email: sabonn.dammarell@lucintel.com
Tel. 972.636.5056
Cell: 208-570-0101